CAS: 1450824-22-2

TD 139 is an advanced small molecule inhibitor, which is sourced from synthetic chemical libraries designed to bind specifically to galectin-3. Galectin-3 is a type of protein that plays a significant role in various biological processes, including inflammation, fibrosis, and cancer progression. By inhibiting galectin-3, TD 139 interferes with its signaling pathways, thereby mitigating pathological processes associated with these conditions. The mode of action of TD 139 involves selective binding to the CRD (carbohydrate recognition domain) of galectin-3, effectively preventing its interaction with biological partners. This disruption in binding leads to the modulation of intracellular signaling pathways that are implicated in inflammatory and fibrotic disorders. The applications of TD 139 are primarily in the realms of research and therapeutic development for diseases with a fibrotic or inflammatory component. Its potential utility in treating conditions such as idiopathic pulmonary fibrosis and certain cancers makes it a significant focus for ongoing scientific studies. TD 139 serves as a tool for scientists exploring the intricate mechanisms of galectin-3 and its involvement in disease pathology, providing a pathway to innovative therapeutic strategies.

TD139

(2R,2'R,3R,3'R,4S,4'S,5R,5'R,6S,6'S)-6,6'-Thiobis(4-(4-(3-Fluorophenyl)-1H-1,2,3-Triazol-1-Yl)-2-(Hydroxymethyl)Tetrahydro-2H-Pyran-3,5-Diol)

TD139 is an inhaled small molecule inhibitor of galectin-3 (Gal-3) with potential anti-fibrotic activity. Cost-effective and quality-assured.